SCHEMBL7916565

SCHEMBL7916565

Cc1ccc2c(c1)SC(C)N2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.41
MAPT P10636 7/20 0.35
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
TDP1 Q9NUW8 3/20 0.35
GAA P10253 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
NOX1 Q9Y5S8 1/20 0.35
HSD17B10 Q99714 4/20 0.34
ALOX15 P16050 3/20 0.34
MAPK1 P28482 1/20 0.34
ALOX12 P18054 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
KDM4E B2RXH2 4/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7924949 0.84 IDO1 (0.38) EPHX2MAPTMEN1KMT2ATDP1
SCHEMBL14818891 0.78 EPHX2 (0.40) EPHX2MAPTMEN1KMT2ATDP1
SCHEMBL18874816 0.78 IDO1 (0.44) MAPTGAANOX1HSD17B10CA12
SCHEMBL16751731 0.78 EPHX2 (0.40) EPHX2MAPTMEN1KMT2ATDP1
SCHEMBL16471403 0.76 SNCA (0.53) MAPTMEN1KMT2ATDP1GAA
SCHEMBL20094335 0.76 KIF11 (0.35) MAPTMEN1KMT2ATDP1GAA
SCHEMBL29051413 0.74 EPHX2 (0.37) EPHX2MAPTMEN1KMT2ATDP1
SCHEMBL12661831 0.72 IDO1 (0.57) MAPTMEN1KMT2ATDP1GAA
SCHEMBL338205 0.72 IDO1 (0.57) MAPTMEN1KMT2ATDP1GAA
SCHEMBL16181708 0.72 IDO1 (0.57) MAPTMEN1KMT2ATDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377640-B1 AZO COMPOUNDS AND PROCESS OF PRODUCING THE SAME AND NOVEL INTERMEDIATE COMPOUNDS USED IN THE PROCESS OF PRODUCING AZO COMPOUNDS FUJIFILM CORP (JP) 2017-05-17 EP disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB EPHX2 2938/4885MAPT 3578/4885MEN1 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.